Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Scandinavian Simvastatin Survival Study Group.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet, 344 (1994), pp. 1383-1389
[2.]
J. Shepherd.
The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction of Scottish men.
Am J Cardiol, 76 (1995), pp. 113-117
[3.]
F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, et al.
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
N Engl J Med, 355 (1996), pp. 1001-1009
[4.]
S.M. Grundy.
National Cholesterol Education Program: second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults.
Circulation, 89 (1994), pp. 1329-1445
[5.]
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).
JAMA, 285 (2001), pp. 2486-2497
[6.]
G. Assmann, H. Schulte.
Relation of high density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience.
Am J Cardiol, 70 (1992), pp. 733-737
[7.]
UK Prospective Diabetes Study Group.
UKPDS 27: plasma lipidslipoproteins at diagnosis of NIDDM by agesex.
Diabetes Care, 20 (1997), pp. 1683-1687
[8.]
J.E. Hokanson, M.A. Austin.
Triglyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: a meta-analysis of population-based prospective study.
J Cardiovasc Risk, 3 (1996), pp. 213-219
[9.]
M.A. Austin, J.E. Hokanson, K.L. Edwards.
Hypertriglyiceridemia as a cardiovascular risk factor.
Am J Cardiol, 81 (1998), pp. 7-12
[10.]
Prevention of coronary heart disease: scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society prepared by international task force for prevention of coronary heart disease.
Nutr Metab Cardiovasc Dis, 2 (1992), pp. 113-156
[11.]
K.R. Feingold, C. Grunfeld, M. Pang, W. Doerrler, R.M. Krauss.
LDL subclass phenotype and triglyceride metabolism in non-insulindependent diabetes.
Arterioscler Thromb, 12 (1992), pp. 1496-1502
[12.]
A.R. Tall.
Plasma high density lipoproteins. Metabolism and relation to atherogenesis.
J Clin Invest, 86 (1990), pp. 379-384
[13.]
G.J. Miller.
Lipoproteins and the haemostatic system in atherothrombotic events.
Clin Haematol, 7 (1994), pp. 713-732
[14.]
W.A. Bradley, F.M. Booyse, S.H. Gianturco.
Fibrinolytic and thrombotic factors in atherosclerosis and ischemic heart disease: the influence of triglyceride rich lipoproteins.
Atherosclerosis, 108 (1994), pp. 531-539
[15.]
H. Cintora, R. Altman, A. Scazziota, F. Cintora, M. Melcon, M. Machain, et al.
Trigliceridemia basal y riesgo cardiovascular: 150-200 mg/dl como “rango crítico” con mayor riesgo aterogénico en individuos aparentemente sanos.
Clin Invest Arteriosclerosis, 11 (1999), pp. 113-120
[16.]
D.H. O’Leary, J.F. Polak, R.A. Kronmall, T.A. Manolio, G.L. Burke, F.K. Jr. Wolfson.
for the Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults.
N Engl J Med, 340 (1999), pp. 14-22
[17.]
M.A. Austin, M.C. King, K.M. Vranizan, R.M. Krauss.
Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk.
Circulation, 82 (1990), pp. 495-506
[18.]
G.M. Reaven.
Banting lecture 1988. Role of insulin resistence in human disease.
Diabetes, 37 (1988), pp. 1597-1606
[19.]
L.A. Simons, T. Dwyer, J. Simons, L. Bernstein, P. Mock, N.S. Poonia, et al.
Chylomicrons and chylomicrons remnants in coronary artery disease: a case-control study.
Atherosclerosis, 65 (1987), pp. 181-189
[20.]
F. Karpe, P. Tornvall, T. Olivecrona, G. Steiner, L.A. Carlson, A. Hamnsten.
Postprandial lipoproteins and progression of coronary atherosclerosis.
Atherosclerosis, 106 (1994), pp. 83-97
[21.]
E. Meyer, H.E. Westerveld, F.C. De Ruyter-Meijstek, M.M. Van Greevenbroock, R. Rienks, H.J. Van Rijn, et al.
Abnormal postprandial apolipoprotein B48 and triglyceride response in normolipidemic women with greater than 70 percent stenotic coronary artery disease. A case-control study.
Atherosclerosis, 124 (1996), pp. 221-235
[22.]
P.H.E. Groot, W.A.H.J. Van Stiphout, X.H. Krauss, H. Jensen, A. Van Tol, T. Van Ramshort, et al.
Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease.
Arterioscler Thromb, 11 (1991), pp. 653-662
[23.]
K. Sakata, N. Miho, M. Shirotani, H. Yoshida, Y. Takada, A. Takada.
Remnant like particle cholesterol is a major risk factor for myocardial infarction in vasoespastic angina with nearly normal coronary artery.
Atherosclerosis, 136 (1998), pp. 225-231
[24.]
J.L. Ellsworth, L.G. Fong, F.B. Kraemer, A.D. Coopner.
Differences in the processing of chylomicrons remnants an B-VLDL by macrophages.
J Lipid Res, 31 (1990), pp. 1399-1411
[25.]
M. Senti, X. Nogues, J.P. Botet, J. Rubies-Prat, F. Vidal Barraquer.
Lipoprotein profile in men with peripheral vascular disease: role of intermediate density lipoproteins and apoprotein E phenotypes.
Circulation, 85 (1992), pp. 30-36
[26.]
J.R. Patsch, G. Miesenböck, T. Hopferwieser, V. Muhlberger, E. Knapp, J.K. Dunn, et al.
Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state.
Arterioscler Thromb, 12 (1992), pp. 1336-1345
[27.]
P.J. Nestel.
Relationship between plasma triglycerides and removal of chylomicrons.
J Clin Invest, 43 (1964), pp. 943-949
[28.]
Cintora H, González C, Machain M, et al. Postprandial triglyceridaemia: a predictor of metabolic disfunction? [abstract]. Proceedings 66th Congress of the European Atherosclerosis Society, 1996; p. 189
[29.]
I. Schrzenmeir.
The phenomenon of a high triglyceride response to an oral lipid load and its link to the metabolic syndrome.
Ann NY Acad Sci, 683 (1993), pp. 302-314
[30.]
E. Cavallero, C. Dachet, D. Neufcour, E. Wirquin, D. Mathe, B. Jacotot.
Postprandial amplification of lipoprotein abnormalities in controlled type II diabetes: relationship to postprandial lipemia and C-peptide/glucagon levels.
Metabolism, 43 (1994), pp. 270-278
[31.]
R.H. Unger.
Lipotoxicity in the pathogenesis of obesity dependent NIDDM: genetic and clinical complications.
Diabetes, 44 (1995), pp. 863-870
Copyright © 2002. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.